Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9833468
SERIAL NO

15084255

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • SAREPTA THERAPEUTICS, INC.;UNIVERSITY OF MARYLAND, BALTIMORE;THE UNITED STATES OF AMERICA, AS REPRESNETED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cao, Kan Bowie, US 8 53
Collins, Francis S Chevy Chase, US 32 509
Erdos, Michael R Severna Park, US 5 53
Kole, Ryszard Corvallis, US 51 1726

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 5, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 5, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00